294 related articles for article (PubMed ID: 23183108)
1. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
[TBL] [Abstract][Full Text] [Related]
2. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
4. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
6. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
[TBL] [Abstract][Full Text] [Related]
7. Involvement of p38 MAP kinase in lipopolysaccharide-induced production of pro- and anti-inflammatory cytokines and prostaglandin E(2) in human choriodecidua.
Shoji T; Yoshida S; Mitsunari M; Miyake N; Tsukihara S; Iwabe T; Harada T; Terakawa N
J Reprod Immunol; 2007 Oct; 75(2):82-90. PubMed ID: 17617469
[TBL] [Abstract][Full Text] [Related]
8. A supercritical CO₂ extract from seabuckthorn leaves inhibits pro-inflammatory mediators via inhibition of mitogen activated protein kinase p38 and transcription factor nuclear factor-κB.
Jayashankar B; Mishra KP; Kumar MS; Udayasankar K; Misra K; Ganju L; Singh SB
Int Immunopharmacol; 2012 Aug; 13(4):461-7. PubMed ID: 22664145
[TBL] [Abstract][Full Text] [Related]
9. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
10. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.
Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC
Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374
[TBL] [Abstract][Full Text] [Related]
11. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
[TBL] [Abstract][Full Text] [Related]
12. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS
Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806
[TBL] [Abstract][Full Text] [Related]
15. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.
Bison S; Razzoli M; Arban R; Michielin F; Bertani S; Carboni L
Eur J Pharmacol; 2011 Jul; 661(1-3):49-56. PubMed ID: 21545800
[TBL] [Abstract][Full Text] [Related]
16. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases.
Foey AD; Parry SL; Williams LM; Feldmann M; Foxwell BM; Brennan FM
J Immunol; 1998 Jan; 160(2):920-8. PubMed ID: 9551930
[TBL] [Abstract][Full Text] [Related]
17. The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay.
Li YY; Bao M; Meurer J; Skuballa W; Bauman JG; Doecke WD; Zollner TM
Immunol Lett; 2008 Apr; 117(1):114-8. PubMed ID: 18241931
[TBL] [Abstract][Full Text] [Related]
18. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways.
Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG
J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902
[TBL] [Abstract][Full Text] [Related]
19. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
[TBL] [Abstract][Full Text] [Related]
20. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.
Asano T; Yamazaki H; Kasahara C; Kubota H; Kontani T; Harayama Y; Ohno K; Mizuhara H; Yokomoto M; Misumi K; Kinoshita T; Ohta M; Takeuchi M
J Med Chem; 2012 Sep; 55(17):7772-85. PubMed ID: 22905713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
